Name:
Methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3-methylbutanoate
Type:
Synthetic cannabinoid
AKA:
FUB–AMB, MMB– FUBINACA, AMB–FUBINACA
Methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3-methylbutanoate image
Synthetic substance, no natural derivative
IUPAC Logo
Methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3-methylbutanoate image
This compound is a synthetic cannabinoid developed in the 2010s. It belongs to a class of substances designed to mimic the effects of THC, the active component of cannabis. Its development is part of ongoing research into cannabinoids and their effects, though its use is regulated due to concerns about safety and abuse potential.
Synthetic Substances Image
Methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3-methylbutanoate is a synthetic cannabinoid with potent psychoactive effects. As an upper, it induces euphoria and altered perception. Short-term effects include increased heart rate and potential anxiety, while long-term use can lead to psychological issues. Overdose risks include severe agitation and cardiovascular problems. Safe use involves cautious dosing, and recent research emphasizes its potency and potential for misuse.
N/A
This synthetic cannabinoid affects cannabinoid receptors, leading to altered perception and mood. Immediate effects include euphoria and relaxation, while long-term use may result in anxiety and cognitive impairments. Research focuses on its potency, safety, and psychological impact.
N/A
This synthetic cannabinoid, part of a group designed to mimic THC, highlights the ongoing evolution of recreational drug use. Synthetic cannabinoids are often used as legal alternatives to cannabis, particularly in regions with strict drug laws. Historically, cannabis has deep cultural roots in religious, medicinal, and recreational use across various societies. The rise of synthetic variants reflects contemporary issues of drug policy, public health, and the search for legal highs. Media coverage often focuses on the health risks and legal battles associated with these substances, emphasizing the challenges in regulating synthetic drugs.
N/A